Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Connective tissue diseases

New evidence-based guidelines for treating SSc

A set of recommendations developed by an international panel of experts could have an impact on the care of patients with systemic sclerosis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Pope, J. E., Ouimet, J. & Krizova, A. Scleroderma treatment differs between experts and general rheumatologists. Arthritis Rheum. 55, 138–145 (2006).

    Article  Google Scholar 

  2. Kowal-Bielecka, O. et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann. Rheum. Dis. doi: 10.1136/ard.2008.096677 (2009).

  3. Thompson, A. E., Shea, B., Welch, V., Fenlon, D. & Pope, J. E. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum. 44, 1841–1847 (2001).

    Article  CAS  Google Scholar 

  4. Pope, J. et al. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database of Systematic Reviews 1998, Issue 2. Art. No.:CD000953. doi: 10.1002/14651858.CD000953 (2000).

  5. Malefant, D., Catton, M. & Pope, J. The efficacy of complementary and alternative medicine in the treatment of Raynaud's phenomenon: a literature review and meta-analysis. Rheumatology (Oxford) (in press).

  6. Johnson, S., Feldman, B., Pope, J. & Tomlinson, G. Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma. J. Rheumatol. 36, 323–329 (2009).

    Article  Google Scholar 

  7. Pope, J. E. Musculoskeletal involvement in scleroderma. Rheum. Dis. Clin. North Am. 29, 391–408 (2003).

    Article  Google Scholar 

  8. Hachulla, E. et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 52, 3792–3800 (2005).

    Article  Google Scholar 

  9. Pope, J. E. et al. The prevalence of pulmonary arterial hypertension in a large Canadian multi-centre cohort of systemic sclerosis subjects. (PHASE study) [abstract]. J. Rheumatol. 31, 1440 (2004).

    Google Scholar 

  10. Villela, R. et al. Assessment of unmet needs in the design of randomized controlled trials and the lack of generalizability for scleroderma treatment. Arthritis Rheum. 59, 706–713 (2008).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pope, J. New evidence-based guidelines for treating SSc. Nat Rev Rheumatol 5, 300–302 (2009). https://doi.org/10.1038/nrrheum.2009.98

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2009.98

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing